Multiple Myeloma

  • Registration Closed

[none]

Robert Orlowski, MD, PhD

MD Anderson Cancer Center

Robert Z. Orlowski, PhD, MD, is the Florence Maude Thomas Cancer Research Professor and Director of the Myeloma Section of the Department of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center.  Dr. Orlowski is internationally recognized for his basic, translational, and clinical research contributions in hematologic malignancies in general, and plasma cell dyscrasias, including multiple myeloma, in particular.  His research teams have been especially involved in understanding the role of components of the ubiquitin-proteasome pathway and associated mechanisms, including Heat shock proteins (HSPs), in tumor pathobiology, and in their viability as therapeutic targets.  These studies have involved the pre-clinical development of novel drugs and rationally designed combinations that were then translated to the clinic in phase I-III clinical trials, leading to multiple regulatory approvals and improved outcomes for tens of thousands of patients.  He obtained both an M.D. and a Ph.D., the latter in Molecular Biophysics and Biochemistry, at the Yale University School of Medicine and Yale University Graduate School, respectively.  Then, after completing his Residency at the Washington University in St. Louis’ Barnes Hospital, he performed fellowships in Adult Hematology and Medical Oncology at the Johns Hopkins University School of Medicine and Johns Hopkins Oncology Center, respectively.  Prior to arriving at MD Anderson, he was the Lenvel Lee Rothrock Associate Professor in Hematology/Oncology and Pharmacology at the University of North Carolina at Chapel Hill’s Lineberger Comprehensive Cancer Center.

Key:

Complete
Failed
Available
Locked
Virtual Session
09/12/2020 at 2:00 PM (EDT)   |  45 minutes
09/12/2020 at 2:00 PM (EDT)   |  45 minutes